AB-CHMINACA is a synthetic cannabinoid rooted in the indazole structure. It is a robust agonist for the CB1 receptor (Ki = 0.78 nM) and CB2 receptor (Ki = 0.45 nM). In rat discrimination studies, AB-CHMINACA demonstrates a complete substitution for Δ9-THC, surpassing its potency by 16. Following the pattern observed in other cannabinoids of its generation, like AB-FUBINACA and AB-PINACA, AB-CHMINACA incorporates a valine amino acid amide residue into its structure, a notable deviation from older cannabinoids that typically featured naphthyl or adamantane residues.

IUPAC name
CAS Number1185887-21-1 
PubChem CID44206133
CompTox Dashboard (EPA)DTXSID101009983
Chemical and physical data
Molar mass356.470 g·mol−1

Side effects

Numerous documented cases have linked this synthetic cannabinoid to seizures, fatalities, and episodes of psychosis.

Legal status

  1. In 2015, AB-CHMINACA was classified as a Schedule I controlled substance in the United States.
  2. Since May 2015, AB-CHMINACA has been categorized as an Anlage II controlled substance in Germany.
  3. As of October 2015, AB-CHMINACA falls under controlled substance regulations in China.
  4. AB-CHMINACA was deemed illegal in Switzerland as of December 2015.
  5. The Russian Federation prohibits the use and possession of AB-CHMINACA, classifying it as an illegal substance.


1. What is AB-CHMINACA?

  • AB-CHMINACA is a synthetic cannabinoid, often referred to as a designer drug known for its psychoactive effects.

2. Are there any health risks associated with AB-CHMINACA use?

  • Yes, AB-CHMINACA has been linked to several health risks, including seizures, deaths, and psychotic episodes. It’s considered a dangerous substance with potential adverse effects.

3. Is AB-CHMINACA legal in the United States?

  • No, AB-CHMINACA is classified as a Schedule I controlled substance in the United States as of 2015. Possession and distribution of this substance are illegal.

4. What is the legal status of AB-CHMINACA in Germany?

  • In Germany, AB-CHMINACA has been classified as an Anlage II controlled substance since May 2015, meaning it is subject to strict regulations and restrictions.

5. Is AB-CHMINACA a controlled substance in China?

  • Yes, as of October 2015, AB-CHMINACA is categorized as a controlled substance in China, making its possession and use illegal.

6. When did AB-CHMINACA become illegal in Switzerland?

  • AB-CHMINACA was declared illegal in Switzerland in December 2015, subject to legal restrictions and penalties.

7. Is AB-CHMINACA banned in the Russian Federation?

  • Yes, AB-CHMINACA is considered an illegal substance in the Russian Federation, making its use and possession unlawful.

8. Where can I find more information about the risks and regulations related to AB-CHMINACA?

  • For more information on the potential health risks and legal status of AB-CHMINACA, it is advisable to consult local health authorities, substance abuse professionals, or relevant drug education resources. Staying informed is essential for making informed and responsible choices.


  1. The Brazilian Health Regulatory Agency (Anvisa) issued Collegiate Board Resolution No. 804 on July 24, 2023, which addresses the control of substances with narcotic, psychotropic, precursor, and other special characteristics, emphasizing the regulatory measures in place. [Reference: Anvisa (2023-07-24). “RDC Nº 804 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial” [Collegiate Board Resolution No. 804 – Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-07-25). Archived from the original on 2023-08-27. Retrieved 2023-08-27.]
  2. Research conducted by Wiley JL and colleagues in September 2015 delves into the affinity and potency of AB-CHMINACA, AB-PINACA, and FUBIMINA in producing effects akin to Δ9-tetrahydrocannabinol (THC) in mice. This study is crucial for understanding the psychoactive properties of these synthetic cannabinoids. [Reference: Wiley JL, Marusich JA, Lefever TW, Antonazzo KR, Wallgren MT, Cortes RA, et al. (September 2015). “AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice”. The Journal of Pharmacology and Experimental Therapeutics. 354 (3): 328–39. doi:10.1124/jpet.115.225326. PMC 4538877. PMID 26105953.]
  3. Information about AB-CHMINACA is also available through Cayman Chemicals, a prominent entity in the field of chemical research. [Reference: AB-CHMINACA, Cayman Chemicals.]
  4. The Drug Enforcement Administration (DEA) provided insights into AB-CHMINACA and related synthetic cannabinoids, discussing factors contributing to their temporary scheduling. [Reference: “N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA), N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and 1-(5-fluoropentyl)-1H-indazol-3-ylmethanone (THJ-2201). Background Information and Evaluation of ‘Three Factor Analysis’ (Factors 4, 5, and 6) for Temporary Scheduling” (PDF). Drug Enforcement Administration. December 2014. Retrieved 7 August 2015.]
  5. The Independent reported on the potential dangers associated with synthetic cannabinoids like AB-CHMINACA, raising concerns about their use as cannabis substitutes. [Reference: Merrill J (5 June 2015). “Vertex: Police warn of ‘ticking time bomb’ of potentially lethal cannabis substitute”. The Independent. Archived from the original on 2015-06-05. Retrieved 2 July 2015.]
  6. The New England Journal of Medicine published an article in July 2015 discussing synthetic cannabinoid-related illnesses and fatalities, highlighting the risks associated with these substances. [Reference: Trecki J, Gerona RR, Schwartz MD (July 2015). “Synthetic Cannabinoid-Related Illnesses and Deaths”. The New England Journal of Medicine. 373 (2): 103–7. doi:10.1056/NEJMp1505328. PMID 26154784.]
  7. Legal Medicine in March 2016 featured a study that identified and quantified metabolites of AB-CHMINACA in a urine specimen, providing insights into the substance’s metabolism. [Reference: Wurita A, Hasegawa K, Minakata K, Gonmori K, Nozawa H, Yamagishi I, et al. (March 2016). “Identification and quantification of metabolites of AB-CHMINACA in a urine specimen of an abuser”. Legal Medicine. 19: 113–8. doi:10.1016/j.legalmed.2015.07.011. PMID 26257317.]
  8. Richland Source reported in September 2015 that no criminal charges were filed in the case of Terrance Moxley’s death, a situation that highlighted the potential dangers of synthetic cannabinoids. [Reference: Schock B (30 September 2015). “No criminal charges in March death of Terrance Moxley”. Richland Source. Retrieved 2 October 2015.]
  9. Clinical Toxicology documented an outbreak of acute delir

Leave a Comment

Your email address will not be published. Required fields are marked *